General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0PRDZZ
ADC Name
Anti-MUC1 ADC
Synonyms
1993-H02-SC239
   Click to Show/Hide
Organization
MERCK PATENT GMBH
Drug Status
Investigative
Drug-to-Antibody Ratio
3.84
Structure
Antibody Name
H02 IgG1
 Antibody Info 
Antigen Name
Mucin-1 (MUC1)
 Antigen Info 
Payload Name
3-aminophenyl-hemiasterlin
 Payload Info 
Linker Name
DBCO Val Cit PABA linker
 Linker Info 
Conjugate Type
DBCO-Azide Click Chemistry Conjugation
Combination Type
SC239
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.65
nM
CVCL_1909
Endocervical adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
2.7
nM
CVCL_0419
Breast adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
3.6
nM
CVCL_0465
Ovarian serous adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
4.5
nM
CVCL_2063
Lung adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
20
nM
CVCL_0455
Lung mucoepidermoid carcinoma
Half Maximal inhibitory Concentration (lC50) 
310
nM
CVCL_1511
Lung adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.65 nM High MUC1 expression (MUC1 +++);Low EGFR expression (EGFR+)
Method Description
A total of 625 cells (WISH) in a volume of 25 uL were seeded in a 384-well flat bottom white polystyrene plate the day before the actual assay started. ADC and free drugs were formulated at 2x starting concentration in cell culture medium and filtered through 0.22um cellulose acetate filtered 2 ml centrifuge tubes. Filter sterilized samples were serial diluted (1:3) under sterile conditions and 25 uL of each dilution was added onto cells in triplicates. Plates were cultured at 37 °C in a C02 incubator for 120 hours. For cell viability measurement, 30 uL of Cell Titer-Glo@ reagent (PromegaT M Corp, Madison, WI) was added into each well, and plates processed as per product instructions. Relative luminescence was measured.

   Click to Show/Hide
In Vitro Model Endocervical adenocarcinoma WISH cells CVCL_1909
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 2.7 nM Low MUC1 expression (MUC1+);High EGFR expression (EGFR+++)
Method Description
A total of 625 cells (MDA-MB-468) in a volume of 25 uL were seeded in a 384-well flat bottom white polystyrene plate the day before the actual assay started. ADC and free drugs were formulated at 2x starting concentration in cell culture medium and filtered through 0.22um cellulose acetate filtered 2 ml centrifuge tubes. Filter sterilized samples were serial diluted (1:3) under sterile conditions and 25 uL of each dilution was added onto cells in triplicates. Plates were cultured at 37 °C in a C02 incubator for 120 hours. For cell viability measurement, 30 uL of Cell Titer-Glo@ reagent (PromegaT M Corp, Madison, WI) was added into each well, and plates processed as per product instructions. Relative luminescence was measured.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma MDA-MB-468 cells CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 3.6 nM Moderate MUC1 expression (MUC1++);Low EGFR expression (EGFR+)
Method Description
A total of 625 cells (OVCAR-3) in a volume of 25 uL were seeded in a 384-well flat bottom white polystyrene plate the day before the actual assay started. ADC and free drugs were formulated at 2x starting concentration in cell culture medium and filtered through 0.22um cellulose acetate filtered 2 ml centrifuge tubes. Filter sterilized samples were serial diluted (1:3) under sterile conditions and 25 uL of each dilution was added onto cells in triplicates. Plates were cultured at 37 °C in a C02 incubator for 120 hours. For cell viability measurement, 30 uL of Cell Titer-Glo@ reagent (PromegaT M Corp, Madison, WI) was added into each well, and plates processed as per product instructions. Relative luminescence was measured.

   Click to Show/Hide
In Vitro Model Ovarian serous adenocarcinoma OVCAR-3 cells CVCL_0465
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 4.5 nM Low MUC1 expression (MUC1+);High EGFR expression (EGFR+++)
Method Description
A total of 625 cells (NCI-H292) were plated in 90 ul cell culture medium per well of a 96-well black/clear flat bottom TC-treated imaging microplate and cultured overnight. A ten-fold starting concentration of ADCs, a respective serial dilution (1:4) were prepared in cell culture medium briefly before use. Wells were supplied with 10 ul ADC or compound solution. Treatment was performed in technical triplicates. The plates were subsequently incubated for 144h. For subsequent cell viability measurement, 100 ul Cell Titer-Glo reagent was pipetted in each well, and plates were further processed according the manufacturer's instructions.

   Click to Show/Hide
In Vitro Model Lung adenocarcinoma HCC827 cells CVCL_2063
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 20 nM Low MUC1 expression (MUC1+);Moderate EGFR expression (EGFR++)
Method Description
A total of 625 cells (NCI-H292) were plated in 90 ul cell culture medium per well of a 96-well black/clear flat bottom TC-treated imaging microplate and cultured overnight. A ten-fold starting concentration of ADCs, a respective serial dilution (1:4) were prepared in cell culture medium briefly before use. Wells were supplied with 10 ul ADC or compound solution. Treatment was performed in technical triplicates. The plates were subsequently incubated for 144h. For subsequent cell viability measurement, 100 ul Cell Titer-Glo reagent was pipetted in each well, and plates were further processed according the manufacturer's instructions.

   Click to Show/Hide
In Vitro Model Lung mucoepidermoid carcinoma NCI-H292 cells CVCL_0455
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 310 nM Low MUC1 expression (MUC1+);Low EGFR expression (EGFR+)
Method Description
A total of 625 cells (NCI-H292) were plated in 90 ul cell culture medium per well of a 96-well black/clear flat bottom TC-treated imaging microplate and cultured overnight. A ten-fold starting concentration of ADCs, a respective serial dilution (1:4) were prepared in cell culture medium briefly before use. Wells were supplied with 10 ul ADC or compound solution. Treatment was performed in technical triplicates. The plates were subsequently incubated for 144h. For subsequent cell viability measurement, 100 ul Cell Titer-Glo reagent was pipetted in each well, and plates were further processed according the manufacturer's instructions.

   Click to Show/Hide
In Vitro Model Lung adenocarcinoma NCI-H1975 cells CVCL_1511
References
Ref 1 Bispecific antibody-drug conjugates targeting EGFR and MUC1 and uses thereof